Previous Close | 0.0900 |
Open | 0.0900 |
Bid | 0.0900 x N/A |
Ask | 0.0900 x N/A |
Day's Range | 0.0900 - 0.0900 |
52 Week Range | 0.0050 - 0.1600 |
Volume | |
Avg. Volume | 72,249 |
Market Cap | 6.285M |
Beta (5Y Monthly) | 0.19 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0400 |
Earnings Date | May 29, 2024 - Jun 03, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
VANCOUVER, British Columbia, April 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and provided a corporate update. 2023 Highlights and Recent Developments On March 27, 2024 we announced a collaboration agreement with Dr. Artem Cherkasov granting R
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, is pleased to announce that members of the Company’s scientific team presented new data on the Company’s novel kt-3000 series at the American Association of Cancer Research (AACR) Annual Meeting at the San D
Rakovina Therapeutics President and Chief Science Officer Mads Daugaard and Dr. Art Cherkasov from the Vancouver Prostate Centre and UBC joined Steve Darling from Proactive to unveil an exciting co...